An interventional study of Group-Based Psychoeducation and Peer Support in Bipolar Disorder (BD) and Psychosis, sponsored by McMaster University. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by McMaster University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 134 studies in Bipolar Disorder with a site in Canada — 24 open to participants now, 28 under way, 4 of them phase 3. Bipolar Disorder · Canada.
Among the 134 studies in Bipolar Disorder with a site in Canada, this one is the 99th largest by planned enrollment of the 118 interventional ones that give a count, is one of 6 that started in 2026, is one of 57 with no phase, reaches primary completion later than 10 of the 27 other live ones, and was the 131st registered.
1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.
Browse Bipolar Disorder studies →24 of the 134 studies in Bipolar Disorder with a site in Canada are open now. Recruiting first, the newest first:
Joshua Rosenblat · Sites in Canada
Ages 18–70
Lakshmi N Yatham · Sites in Canada
Ages 19–65
University of Ottawa · Sites in Canada
Ages 18–55
University of Manitoba · Sites in Canada
Ages 18+
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18–65
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
134 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 21 · Phase 3 27 · Phase 4 10
First in 1999; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 64 across 1,282 interventional studies indexed under Bipolar Disorder.
Median enrollment 42 across the 118 interventional studies, 175 across the 16 observational. Of the 88 that completed or were terminated, 14 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 134 have an industry lead sponsor. The 10 most frequent:
McMaster University is the lead sponsor of 742 studies on the registry; 127 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 3 (43%) have results posted.
McMaster University has 2 studies filed under Bipolar Disorder — fewer than ten, so there is no comparison to draw.
5 of the studies in Bipolar Disorder with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06560957University of OttawaSYNCED - SYNChronized Eating in Bipolar Depression Study | 2026-12-26 |
| NCT07213492McMaster UniversityMultimodal Intervention to Support Hospital-to-Community Transition in Bipolar Disorder | 2027-05-01 |
| NCT01980147Nova Scotia Health AuthoritySkills for Wellness | 2027-06-30 |
| NCT07510646Vielight Inc.Transcranial Photobiomodulation for Bipolar Depression | 2027-07-01 |
| NCT07108257Sunnybrook Health Sciences CentreMagnetic Resonance-Guided Focused Ultrasound Bilateral Capsulotomy for the Treatment of Refractory Bipolar Depression | 2027-09-16 |
Add all 5 to your calendar (.ics) → With an account.
Among the 134 studies in Bipolar Disorder with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
People with bipolar disorder (BD) are at high risk of relapse following hospital discharge, partly due to a lack of BD-specific expertise and resources within community services required for comprehensive treatment. Although clinical guidelines recommend combining medication and psychosocial support, and research shows that early intervention is associated with improved outcomes, no structured care programs currently exist for individuals in the early stages of BD, contributing to chronic illness progression and preventable hospitalizations. This open-label pilot trial will assess the feasibility, acceptability, and preliminary effectiveness of a structured care pathway to support the transition from hospital to community care. The intervention includes group-based psychoeducation, individual peer support, and personalized support for community healthcare providers to improve illness insight, treatment adherence, and symptom management.
This is a 6-month, open-label pilot study of the feasibility, acceptability, and preliminary effectiveness of a multimodal transitional-care intervention for individuals with BD who have recently been discharged from the hospital. The intervention comprises a brief group psychoeducation program (6 clinician-facilitated sessions delivered over up to 8 weeks), individualized peer support (biweekly one-on-one sessions for \~12 total across 6 months), and optional personalized support for participants' primary healthcare providers (two collaborative sessions over 6 months offering guideline-based recommendations and access/training to a clinical decision-support app). Ten patient-participants who meet the inclusion criteria will be enrolled over 6 months; this sample will be used to estimate recruitment, retention, adherence, satisfaction, and safety parameters, and to inform power and procedures for a subsequent randomized controlled trial. Participants will be recruited from St. Joseph's Healthcare Hamilton (SJHH) outpatient clinics, the community and the ENABLE research registry at SJHH (Hamilton, ON, Canada). Eligible adults are 18-35 years old with a BD diagnosis within the past 24 months and a history of psychosis and/or limited illness insight; all must meet inclusion/exclusion criteria and provide written informed consent. After obtaining consent, eligibility will be confirmed with the Mini-International Neuropsychiatric Interview (MINI) and the Mood Disorders Insight Scale (MDIS). Study visits occur at three timepoints: baseline, post-psychoeducation, and post-multimodal intervention (6 months). At each assessment time point, clinicians and/or patient-participants will complete validated measures; socio-demographic and clinical history will be collected at baseline. Feasibility will be assessed through recruitment, enrollment, adherence (session attendance/completion), and retention metrics; acceptability through patient-participant and healthcare-provider satisfaction questionnaires; and safety through prospective monitoring of emergent symptoms, acute relapse, emergency visits, hospitalizations, and suicide-related events. Data will be summarized primarily with descriptive statistics (means, standard deviations, frequencies); exploratory pre-post comparisons (e.g., t-tests or chi-square) will evaluate the signal of change in symptoms, insight, functioning, lifestyle, and quality of life. The results of this study will determine whether delivering a structured psychoeducation + peer-support + provider-support care pathway during the transition from hospital to community is feasible and acceptable for early-stage BD, and will guide sample-size calculations, procedures, and implementation strategies for a subsequent randomized controlled trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants receive a 6-month structured intervention including: (1) 6 sessions of group-based psychoeducation, (2) biweekly peer support for individuals and families, and (3) two sessions of personalized clinical guidance for community healthcare providers.
Behavioral: Group-Based Psychoeducation · Behavioral: Peer Support · Behavioral: Personalized Support for Community Healthcare Provider
Participants attend a six-session, group-based psychoeducation program delivered over 8 weeks. Sessions focus on improving insight into bipolar disorder, relapse prevention, lifestyle strategies (e.g., sleep, nutrition, substance use), and digital literacy. The aim is to enhance understanding of illness and support long-term functioning.
Trained peer support workers provide biweekly sessions over 6 months to participants. The sessions are based on the CANMAT/ISBD Patient and Family Guide and include emotional support, psychoeducation, and shared experience. Each participant receives up to 12 sessions aimed at improving engagement and understanding of illness.
The research team provides two personalized support sessions over 6 months to each participant's healthcare provider (e.g., family doctor or psychiatrist). Support includes treatment recommendations based on the CANMAT/ISBD 2018 Guidelines and training on the C-IMPACT BD web-based clinical decision support tool.
Feasibility of the Multi-Modal Transitional Care Intervention
Feasibility will be assessed using three descriptive indicators: 1) Recruitment rate: the proportion of eligible patient-participants and community healthcare providers who consent to participate. 2) Retention rate: the proportion of enrolled participants who remain in the study until the final follow-up. 3) Intervention adherence: participant adherence to each intervention component, including the number of sessions attended and number of dropouts. Each indicator will be analyzed separately to determine the feasibility of implementing the multi-modal transitional care intervention.
Time frame: From enrollment to the end of intervention at 6 months.
Acceptability of the Multi-Modal Transitional Care Intervention
Acceptability will be measured using post-intervention surveys completed by patient-participants and community healthcare providers. Surveys will assess satisfaction and perceived usefulness of the intervention using Likert-scale items, with the option to provide additional information via open-ended questions.
Time frame: Administered at the end of the intervention (Month 6).
Change in Depression Symptoms (MADRS)
Clinician-rated 10-item scale assessing depressive symptoms over the past 7 days. Items are rated on a 7-point Likert scale, with higher scores indicating more severe symptoms.
Time frame: Baseline and Month 6 (end of intervention).
Change in Mania Symptoms (YMRS)
Clinician-rated 11-item scale assessing manic symptoms using clinical interview and observation. Items scored 0-4 or 0-8, with higher scores indicating more severe mania.
Time frame: Baseline and Month 6 (end of intervention).
Change in Anxiety Symptoms (GAD-7)
7-item self-report scale assessing anxiety over the past 2 weeks. Items scored 0-3; higher scores reflect greater anxiety.
Time frame: Baseline, Mid-intervention (Month 3), and Month 6 (end of intervention).
Change in Depression Severity (Patient Health Questionnaire) (PHQ-9)
9-item self-report scale evaluating the presence and severity of depression symptoms over the past 2 weeks. Each item scored 0-3; higher scores indicate greater severity.
Time frame: Baseline, Mid-intervention (Month 3), and Month 6 (end of intervention).
Change in Insight (MDIS)
Self-report scale assessing insight in mood disorders. Participants respond "Agree," "Disagree," or "Unsure." Higher scores indicate better insight.
Time frame: Baseline and Month 6 (end of intervention).
Change in Psychosocial Functioning (FAST)
Clinician-administered scale assessing functioning across six domains (autonomy, work, cognition, finances, relationships, leisure). Each item rated 0-3.
Time frame: Baseline and Month 6 (end of intervention).
Change in Cognitive Complaints (COBRA)
16-item self-report questionnaire measuring cognitive dysfunction in bipolar disorder. Each item scored 0-3; higher scores indicate more impairment.
Time frame: Baseline and Month 6 (end of intervention).
Change in Quality of Life (Q-LES-Q-SF)
16-item self-report scale assessing satisfaction and enjoyment in multiple life areas over the past week. Items rated on a 5-point scale.
Time frame: Baseline, Mid-intervention (Month 3), and Month 6 (end of intervention).
Change in Lifestyle Behaviours (SMILE)
Self-report scale measuring behaviours across seven lifestyle domains (diet and nutrition, substance use, physical activity, stress management, restorative sleep, social support, and environmental exposures). Items scored on a 4-point scale; higher scores reflect healthier lifestyle.
Time frame: Baseline and Month 6 (end of intervention).
Safety Monitoring: Relapse, Hospitalization, and Risk
Monitoring and documentation of adverse events including psychiatric relapse, hospitalizations, and suicide attempts throughout the intervention period.
Time frame: Throughout the 6-month intervention period.
Sociodemographic Factors
Demographic and clinical background data will be collected, including gender, age, ethnicity, marital status, education level, income, medical and psychiatric history, family history of psychiatric disorders, medication usage, and treatment history.
Time frame: Baseline and Month 6 (end of intervention).
Plan to share: No — Currently, we do not have the plan of individual participant data (IPD) sharing.
Started Jun 2026 (actual). Primary completion is estimated for May 2027, 11 months after the start.
Of 361 non-industry interventional studies with no phase under Bipolar Disorder, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's planned 11 months is below that.
Counting every sponsor, half of 363 studies reached it within 37 months; a quarter within 23 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.